Advertisement

Metabolomics

, 14:23 | Cite as

Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case–control study

  • Nwora Lance Okeke
  • Damian M. Craig
  • Michael J. Muehlbauer
  • Olga Ilkayeva
  • Meredith E. Clement
  • Susanna Naggie
  • Svati H. Shah
Short Communication

Abstract

Introduction

Persons living with HIV (PLWH) are at higher risk for cardiovascular disease (CVD) events than uninfected persons. Current risk-stratification methods to define PLWH at highest risk for CVD events are lacking.

Methods

Using tandem flow injection mass spectrometry, we quantified plasma levels of 60 metabolites in 24 matched pairs of PLWH [1:1 with and without known coronary artery disease (CAD)]. Metabolite levels were reduced to interpretable factors using principal components analysis.

Results

Factors derived from short-chain dicarboxylacylcarnitines (SCDA) (p = 0.08) and glutamine/valine (p = 0.003) were elevated in CAD cases compared to controls.

Conclusion

SCDAs and glutamine/valine may be valuable markers of cardiovascular risk among persons living with HIV in the future, pending validation in larger cohorts.

Keywords

Cardiovascular disease HIV Metabolomics Acute coronary syndrome Myocardial infarction 

Notes

Funding

This research was funded by the National Heart, Lung and Blood Institute (R56 HL129880) and by the Duke Centers for AIDS Research (P30 AI064518).

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

Research involving human participants and/or animals

Ethical approval for the use of patient clinical data and specimens were approved by the Duke University Institutional Review Board.

Informed consent

Patient consent was obtained at the time of sample collection for the Duke HIV Biorepository with the understanding that their samples would be used for future research studies.

References

  1. An, J., Muoio, D. M., Shiota, M., Fujimoto, Y., Cline, G. W., Shulman, G. I., Koves, T. R., et al. (2004). Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nature Medicine, 10, 268–274.CrossRefPubMedGoogle Scholar
  2. Ferrara, C. T., Wang, P., Neto, E. C., Stevens, R. D., Bain, J. R., Wenner, B. R., et al. (2008). Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLoS Genetics, 4, e1000034.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Freiberg, M. S., Chang, C. C., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. L., et al. (2013) HIV infection and the risk of acute myocardial infarction. JAMA Internal Medicine, 173, 614–622.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Friis-Moller, N., Thiebaut, R., Reiss, P., Weber, R., Monforte, A. D., De Wit, S., et al. (2010). Predicting the risk of cardiovascular disease in HIV-infected patients: The data collection on adverse effects of anti-HIV drugs study. European Journal of Preventive Cardiology, 17, 491–501.CrossRefGoogle Scholar
  5. Hsue, P. Y., Hunt, P. W., Schnell, A., Kalapus, S. C., Hoh, R., Ganz, P., et al. (2009). Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS, 23, 1059–1067.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Kraus, W. E., Muoio, D. M., Stevens, R., Craig, D., Bain, J. R., Grass, E., et al. (2015). Metabolomic quantitative trait loci (mQTL) mapping implicates the ubiquitin proteasome system in cardiovascular disease pathogenesis. PLoS Genetics, 11, e1005553.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Newgard, C. B., An, J., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Lien, L. F., et al. (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabolism, 9, 311–326.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Shah, A. A., Craig, D. M., Sebek, J. K., Haynes, C., Stevens, R. C., Muehlbauer, M. J., et al. (2012a). Metabolic profiles predict adverse events after coronary artery bypass grafting. The Journal of Thoracic and Cardiovascular Surgery, 143, 873–878.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Shah, S. H., Bain, J. R., Muehlbauer, M. J., Stevens, R. D., Crosslin, D. R., Haynes, C., et al. (2010) Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circulation: Cardiovascular Genetics, 3, 207–214.Google Scholar
  10. Shah, S. H., Hauser, E. R., Bain, J. R., Muehlbauer, M. J., Haynes, C., Stevens, R. D., et al. (2009). High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Molecular Systems Biology, 5, 258.CrossRefPubMedPubMedCentralGoogle Scholar
  11. Shah, S. H., Sun, J. L., Stevens, R. D., Bain, J. R., Muehlbauer, M. J., Pieper, K. S., et al. (2012b). Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. American Heart Journal, 163, 844e1–850e1.CrossRefGoogle Scholar
  12. Thompson-Paul, A. M., Lichtenstein, K. A., Armon, C., Palella, F. J., Skarbinski, J. R., Chmiel, J. S., et al. (2016). Cardiovascular disease risk prediction in the HIV outpatient study. Clinical Infectious Diseases, 63, 1508–1516.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Department of MedicineDuke University Medical CenterDurhamUSA
  2. 2.Duke Molecular Physiology InstituteDurhamUSA
  3. 3.Duke Clinical Research InstituteDurhamUSA
  4. 4.Duke Global Health InstituteDurhamUSA
  5. 5.Division of Cardiology, Department of MedicineDuke University Medical CenterDurhamUSA

Personalised recommendations